{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250698","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.751078+00:00","generated_at":"2026-05-17T02:10:25.216569+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Galera Therapeutics sells avasopasem and rucosopasem assets to Biossil Inc.","bullets":["Sold all dismutase mimetic assets including avasopasem (GC4419) and rucosopasem (GC4711) to Biossil Inc., a Canadian company.","Transaction closed Oct 15, 2025; Blackstone Agreement assigned to Biossil on Oct 21, 2025.","Blackstone will look solely to Biossil for all obligations under the Amended Blackstone Agreement; Galera relieved of those liabilities.","No purchase price or deal financial terms disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250698","json":"https://secwatch.observer/filing/0001193125-25-250698.json","markdown":"https://secwatch.observer/filing/0001193125-25-250698.md","text":"https://secwatch.observer/filing/0001193125-25-250698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312525250698/0001193125-25-250698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312525250698/d904873d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:10:25.216569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}